Deep Track Capital ALGS Position
Active5-Fund ConvergenceDeep Track Capital held their position in Aligos Therapeutics, Inc. (ALGS) in Q4 2025, holding $4.1M worth of shares across 444,110 shares.
The position was first reported in Q4 2023 and has been tracked across 9 quarterly 13F filings.
ALGS is a convergence signal: 5 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 2 readout for ALG-000184 in 349 days (Mar 31, 2027), making the timing of Deep Track's position particularly relevant.
About Aligos Therapeutics, Inc.
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB. The company also develops ALG-020572, an antisense oligonucleotide to prevent HBsAg translation and secretion; and ALG-055009, a small molecule THR-ß agonist that is in the Phase 1a/1b for the treatment of non-alcoholic steatohepatitis(NASH). In addition, it develops siRNA drug candidate, ALG-125755, as well as ALG-125097 and ALG-125819, demonstrated potent inhibition of HBsAg release from HBV-infected cells. It has entered into license and collaboration agreements with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; Emory University to provide hepatitis B virus capsid assembly modulator technology; research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors; and Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH. The company was incorporated in 2018 and is headquartered in South San Francisco, California.
Full company profile →Short Interest
5.6%
7.7 days to cover
Deep Track Capital ALGS Position History
Frequently Asked Questions
Does Deep Track Capital own ALGS?
Yes. As of Q4 2025, Deep Track Capital holds 444,110 shares of Aligos Therapeutics, Inc. (ALGS) valued at $4.1M. This data comes from their SEC 13F filing.
How many hedge funds own ALGS?
5 specialist biotech hedge funds currently hold ALGS, including EcoR1 Capital, Baker Bros. Advisors, Boxer Capital and 1 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Deep Track Capital first buy ALGS?
Deep Track Capital's position in ALGS was first reported in Q4 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Deep Track Capital's ALGS position increasing or decreasing?
Deep Track Capital held their ALGS position unchanged in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
ALGSCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Deep Track CapitalPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →